Sorry, you need to enable JavaScript to visit this website.

INLYTA® (axitinib) Indications and Usage

1 INDICATIONS AND USAGE

1.1 First-Line Advanced Renal Cell Carcinoma

INLYTA in combination with avelumab is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC).

INLYTA in combination with pembrolizumab is indicated for the first-line treatment of patients with advanced renal cell carcinoma.

1.2 Second-Line Advanced Renal Cell Carcinoma

INLYTA as a single agent is indicated for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.

What's New

No Current Announcements.

Contact Pfizer Medical

Report an Adverse Event
1-800-438-1985

Search

Please enter your search term(s) for INLYTA®